Breakout Bulletin: August 24-August 28

You’re busy. Between patients, prior authorizations, inbox messages, and everything else on your plate, keeping up with the literature is the first thing that slips. Dermatology Times NP/PA Connect is here to make sure it doesn’t. Each week, we pull the most clinically relevant news from across dermatology and bring it straight to your inbox — what’s new, what it means, and what’s worth watching. This week: a large meta-analysis reframes how you counsel patients on vitiligo and skin cancer risk, an interactive case tests your next move on a JAK inhibitor lipid spike, Verrica closes enrollment in its phase 3 common warts trial, we break down the DCNP and CAQ-Derm certification pathways, and a quiz puts your Tudriqev knowledge to the test

Vitiligo Doesn't Raise Skin Cancer Risk the Way You Might Assume

A new PRISMA-based meta-analysis pooled 14 studies covering 454,307 patients with vitiligo and more than 3.5 million controls, and it found something many patients don't expect: significantly lower odds of squamous cell carcinoma (SCC) in vitiligo, with an odds ratio of 0.76 (95% CI, 0.57-0.99; P = .045).¹ Basal cell carcinoma, overall nonmelanoma skin cancer, and melanoma all trended lower too, though those associations didn't reach statistical significance.

The likely explanation isn't melanin protection, since vitiligo involves melanocyte loss. Researchers point instead to the disease's immune biology. Vitiligo involves CD8+ T-cell activity and interferon signaling against melanocytes, and some of the targeted antigens overlap with those on melanoma cells, so heightened immune surveillance may partly explain the inverse association.¹ When the largest heterogeneous study was removed from a melanoma sensitivity analysis, the protective association became significant, with an OR of 0.33 (95% CI, 0.13-0.84).¹

Phototherapy came out reassuringly neutral. Pooled estimates for phototherapy-exposed patients were numerically higher for melanoma (OR, 1.87) and NMSC (OR, 1.46), but neither reached significance, and inconsistent dosing and modality across studies made a clear signal hard to establish.¹ This is an association, not proof that vitiligo itself is protective, and it shouldn't be used to justify skipping routine skin exams.

▶ Why it matters: This gives you data-backed reassurance for patients worried that vitiligo or narrowband UVB therapy raises their skin cancer risk, without changing your routine surveillance recommendations.

MORE ON SKIN CANCER

This JAK Case Tests Whether You'd Pull the Plug Over an LDL Spike

This week's Derm Case Files walks through a 42-year-old woman with moderate to severe atopic dermatitis (BSA 24%, EASI 30) who had already failed topicals, phototherapy, and dupilumab. With a BMI of 30, baseline LDL of 108 mg/dL, PCOS, and a maternal history of myocardial infarction at age 58, she started upadacitinib 15 mg daily after baseline labs and shared decision-making.²

At 12 weeks she was clear, BSA down to roughly 3% with an 85% EASI improvement, and sleeping normally. But her repeat lipid panel told a different story: LDL had climbed from 108 to 192 mg/dL, with a 10-year ASCVD risk of 5.9%. The case asks whether that's reason enough to stop the drug.

The care team didn't discontinue. They looped in her primary care provider, started rosuvastatin 10 mg, and continued upadacitinib. At 3-month follow-up her atopic dermatitis remained controlled, she tolerated the statin without issue, and her cholesterol had stabilized.

▶ Why it matters: Lipid elevation on JAK inhibitors is a predictable, manageable finding, not an automatic reason to discontinue an otherwise effective treatment. Baseline labs, interval monitoring, and PCP collaboration keep patients on therapy safely.

The First Prescription Option for Common Warts Just Got Closer

Verrica Pharmaceuticals has completed enrollment in COVE-2, the first pivotal phase 3 trial evaluating YCANTH (cantharidin) for common warts, after an independent statistician's interim power analysis found no additional patients were needed. The companion trial, COVE-3, has passed 50% of its target enrollment. Topline data from COVE-2 are expected in the first quarter of 2027, with the rest of the phase 3 program reading out by mid-2027.⁴

Common warts affect an estimated 22 million people in the US, and there is currently no FDA-approved prescription drug for the condition. YCANTH is already approved for molluscum contagiosum in patients 2 years and older; a positive phase 3 program could make it the first approved prescription option for warts as well.⁴

If the Phase 3 program is successful, YCANTH has the potential to become the first FDA-approved prescription drug treatment for common warts.— Noah L. Rosenberg, MD, Chief Medical Officer, Verrica Pharmaceuticals

For now, this is an enrollment milestone, not efficacy or safety data. COVE-2 remains fully blinded, and the announcement doesn't include any results.

▶ Why it matters: Nothing changes in how you counsel or treat common warts today. Enrollment completion means a phase 3 readout is on the horizon in 2027, not that a new option exists yet.

Why So Few NPs and PAs in Dermatology Are Board Certified

NPs and PAs delivered 27.4% of dermatology office visits in 2020, up from 15.5% in 2013, and they account for 55.6% of dermatology providers in micropolitan areas and 87.8% in rural areas.² Despite that footprint, specialty certification isn't required to practice, and a 2024 workforce survey of 10,275 NPs found that only 0.3% reported a dermatology specialty certification.

The DCNP exam for NPs requires 3,000 hours of dermatology practice within 3 years, APRN licensure, and passing 175 questions weighted toward assessment, diagnosis, prescribing, and procedures. It costs $400 and renews every 3 years. As of July 2025, only 588 NPs nationwide held it. CAQ-Derm, the newer PA credential launched in 2023, requires 4,000 hours over 6 years plus 75 category 1 dermatology CME credits.²

Neither credential has outcomes data linking it to better diagnostic accuracy or patient outcomes yet. What CAQ-Derm holders do report is professional payoff: more than 40% pursued a promotion, about half saw a pay increase, and roughly two-thirds said patients treated them with more respect. The review's authors point to cardiology, where the American College of Cardiology published formal NP and PA competencies in 2020, as a possible model for dermatology.²

▶ Why it matters: Certification remains optional and unproven on outcomes, but for PAs weighing CAQ-Derm, the career benefits reported so far may be reason enough to pursue it.

Test Your Knowledge on Tudriqev's Accelerated Approval

Tudriqev (vusolimogene oderparepvec-wtpg), combined with nivolumab, received FDA accelerated approval for adults with unresectable or metastatic cutaneous melanoma that progressed on anti-PD-1 therapy, based on objective response rate and duration of response.⁵ This week's quiz, built around an interview with Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, tests whether you can explain the drug's abscopal effect (immune responses in uninjected lesions), when an interventional radiologist should be involved for visceral injections, and which end points the confirmatory IGNYTE-3 trial is tracking (overall survival and progression-free survival).

▶ Why it matters: If you have PD-1-refractory melanoma patients, understanding how this oncolytic immunotherapy works, and how it's delivered, prepares you to have an informed conversation about it as an option.

References

1. Gaumond SI, Andrade LF, Warp PV, et al. Vitiligo and skin cancer risk: a systematic review and meta-analysis with subtype and phototherapy stratification. JEADV Clin Pract. Published online 2026. doi:10.1002/jvc2.70418
2. Smith L, Horzempa I. Advancing standards: the role of specialty certification in advanced practice practitioners in dermatology practice. J Clin Aesthet Dermatol. 2026;19(7-8 Suppl 1). https://jcadonline.com/advancing-standards-the-role-of-specialty-certification-in-advanced-practice-practitioners-in-dermatology-practice/
3. Duerr H. JAK Workshop: Case-Based Roundtable Discussion. Presented at: 2026 Elevate-Derm Summer Conference; July 29-August 2, 2026; San Diego, CA. https://www.dermatologytimes.com/view/jaks-in-practice-panel-discusses-case-pearls-at-elevate-derm-conference
4. Verrica Pharmaceuticals announces completion of enrollment in first pivotal phase 3 trial (COVE-2) evaluating YCANTH for the treatment of common warts, with topline data expected Q1 2027. News release. Verrica Pharmaceuticals Inc. August 27, 2026. Accessed August 27, 2026. https://www.biospace.com/press-releases/verrica-pharmaceuticals-announces-completion-of-enrollment-in-first-pivotal-phase-3-trial-cove-2-evaluating-ycanth-for-the-treatment-of-common-warts-with-topline-data-expected-q1-2027
5. FDA approves new engineered viral immunotherapy for patients with treatment-resistant advanced melanoma. News release. FDA. November 25, 2025. Accessed August 21, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma